FDA Approves LYTENAVA for Wet Macular Degeneration Treatment

The U.S. FDA has approved LYTENAVA (bevacizumab-vikg) for treating neovascular age-related macular degeneration (nAMD), also known as wet AMD. This approval provides an FDA-sanctioned ophthalmic bevacizumab specifically for eye conditions, backed by rigorous clinical evidence. Outlook Therapeutics plans to launch the treatment in the U.S. by year-end, offering a new option for retina specialists and patients.